Device Trial Radar · NCT02209610
Premature Fatigue in Veterans With Heart Failure: Neuronal Influences
Last checked: Nov 19, 2026Latest source record: Aug 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Jul 1, 2015
Primary completion
Jan 15, 2017
Study completion Jan 15, 2017
Sponsor
- Lead sponsor
- VA Office of Research and DevelopmentFederal agency
- Sponsor type
- Federal agency
- Collaborators
- University of Utah
- First posted
- Aug 6, 2014
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Basic science
- FDA-regulated device
- No
- Who can join
- All sexes, from 20 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A hallmark of patients with heart failure (HF) is premature fatigue which impairs their quality of life and depicts a major source of morbidity. Premature fatigue may be attributed to a) contraction-induced transient changes within muscles (i.e. peripheral fatigue) and/or b) failure of the central nervous system to 'drive' / activate locomotor muscles (i.e. central fatigue). Both determinants of fatigue can lead to a reduction in a muscle's force and power generating capacity and to a compromised ability to perform whole body activities (e.g. walking). Recent findings in health have documented that group III/IV afferent fibers from the working muscle play a critical role in the development of both components of fatigue. Specifically, group III/IV muscle afferents limit central motor drive (CMD) during exercise and thereby exaggerate the development of central fatigue. In contrast, muscle afferents optimize muscle O2 delivery through the precise regulation of circulation and ventilation during exercise and thereby attenuate the development of peripheral fatigue.
Conditions
- Heart Failure
Interventions
Electrical and Magnetic Nerve StimulatorsDevice
Stimulation of motor nerve and central nervous system
Intrathecal FentanylDrug
Mu-opioid receptor agonist
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximal Voluntary Quadriceps Force [% Change From Baseline]Time frame: 1 minute after exercise on study day
- Quadriceps Twitch Force and Voluntary Activation (% Change From Baseline)Time frame: During (20 second intervals) and 1 minute after exercise on study day
- Muscle Afferent AffectTime frame: 1 minute after exercise on study day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
VA Salt Lake City Health Care System, Salt Lake City, UT
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.